Alkahest Appoints World Leading Experts to Inaugural Scientific Advisory Board

SAN CARLOS, Calif., Oct. 5, 2015 /PRNewswire/ -- Alkahest, Inc., an emerging leader in the development of function-restoring and enhancing therapies for the treatment of age-related health conditions, today announced the appointment of leading experts to its newly formed scientific advisory board. The newly appointed SAB will serve as a strategic resource to Alkahest as it continues to develop its technology platform and product candidates based on naturally occurring factors from blood and plasma.

"We are thrilled with the addition of these experts in the basic biology and treatment of neurodegenerative and other disorders of aging to our team of advisors," said Karoly Nikolich PhD, Co-Founder, Chairman and Chief Executive Officer of Alkahest. "The background and experience our SAB members bring to Alkahest will be invaluable in guiding our research and development activities."

The inaugural members of Alkahest's scientific advisory board include:

• Tony Wyss-Coray PhD, (Chairman) Professor, Neurology & Neurological Sciences, Stanford University Medical School, and Co-Director Stanford Alzheimer's Disease Research Center
• Lennart Mucke MD, Director of the Gladstone Institute of Neurological Disease, and Professor of Neuroscience & Neurology at the University of California, San Francisco 
• Tom Rando MD, PhD, Professor, Neurology and Neurological Sciences, Director, Glenn Laboratories for the Biology of Aging, and Deputy Director, Stanford Center on Longevity, Stanford University Medical School
• Eric Reiman MD, Professor of Psychiatry, University of Arizona, and Executive Director, Banner Alzheimer's Institute
• Lee Rubin PhD, Professor, Stem Cell and Regenerative Biology, Harvard University, and Director of Translational Medicine at the Harvard Stem Cell Institute
• Saul Villeda PhD, Faculty Fellow, University of California, San Francisco

"The launch of Alkahest's scientific advisory board underscores our commitment to continuing the development of innovative therapies that may extend life quality," said Tony Wyss-Coray, Ph.D., Stanford University Professor and Alkahest Co-Founder.  "Alkahest's technology platform is focused on mammalian biology and the behavioral, proteomic and structural changes associated with aging in animals. These additions to our team further position Alkahest to successfully reach our goal of bringing transformative treatments to patients living with cognitive and other disorders of aging."

About Alkahest
Alkahest is developing therapies derived from blood and plasma to treat neurological diseases, with an emphasis on cognitive dysfunction and dementia -- key medical challenges of our generation.  The company's breakthrough research has demonstrated that factors in blood plasma of young animals are able to reverse brain deficits in normal aging and Alzheimer's disease models in animals.  Clinical studies are being conducted in patients with different types of dementia and other neurodegenerative diseases. Alkahest is a private company based in San Carlos, CA, with investors including Barcelona, Spain-based Grifols, a global healthcare company and leading producer of plasma therapies, as well as a collaboration and commercialization partner.  For further information, see www.alkahest.com.

SOURCE Alkahest, Inc.

Related Links

http://www.alkahest.com